US Stock MarketDetailed Quotes

SABS SAB Biotherapeutics

Watchlist
  • 1.6200
  • +0.0100+0.62%
Close Mar 17 16:00 ET
14.95MMarket Cap-0.26P/E (TTM)

About SAB Biotherapeutics Company

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.

Company Profile

SymbolSABS
Company NameSAB Biotherapeutics
Listing DateFeb 9, 2021
Founded2014
CEOMr. Samuel J. Reich
MarketNASDAQ
Employees57
Fiscal Year Ends12-31
Address777 West 41st Street,Suite 401
CityMiami Beach
ProvinceFlorida
CountryUnited States of America
Zip Code33140
Phone1-605-679-6980

Company Executives

  • Name
  • Position
  • Salary
  • Samuel J. Reich
  • Chief Executive Officer and Director
  • 565.80K
  • Dr. Alexandra Kropotova, M.D.
  • Chief Medical Officer and Executive Vice President
  • 921.58K
  • Christoph Lawrence Bausch
  • Chief Operating Officer
  • 549.32K
  • Lucy To
  • Chief Financial Officer
  • --
  • Mark William Conley, C.P.A.
  • Vice President, Finance
  • --
  • Dr. Eddie J. Sullivan, PhD
  • Director and President
  • 202.60K
  • David Link, M.B.A.
  • Vice Chairman of the Board
  • 25.00K
  • Dr. Jay S. Skyler,M.D.,M.A.C.P.
  • Director
  • --
  • Christine Hamilton, M.B.A.
  • Independent Director
  • 25.00K
  • Admiral Scott Giberson, (Ret.)
  • Independent Director
  • 25.00K
  • Helen Katherine Ellias
  • Independent Director
  • --
  • Erick J. Lucera, C.F.A.
  • Independent Director
  • 26.93K
  • Andrew D. Moin
  • Independent Director
  • --
  • Dr. William J. Polvino, M.D.
  • Independent Director
  • 25.00K
  • Jeffrey G. Spragens
  • Independent Director
  • 25.00K

Trending Stocks

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Unlock Now
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More